GLOW
Fifteen months of two oral drugs cut the risk of progression by nearly 80% versus chemoimmunotherapy in older patients, and later showed a survival advantage.
PFS HR 0.216 (95% CI 0.131-0.357); uMRD in marrow 51.9% vs 17.1%; 4-year OS HR 0.487 (2023 update). NEJM Evidence 2022. EU approval of the fixed-duration regimen 2022; not FDA-approved in the US.
- The treated group had about 78 percent lower chance of the event at any given time (hazard ratio 0.216).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- 51.9 vs 17.1 out of 100 had no detectable disease on sensitive tests with Ibrutinib + venetoclax compared with Chlorambucil + obinutuzumab; 34.8 more per 100.
- Roughly one extra person helped for every 3 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Previously untreated CLL, age ≥65 or with comorbidities, no del(17p)/TP53: fixed-duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (17p); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
211 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Ibrutinib + venetoclax | 106 | — | 0.216 (0.131–0.357) | <0.0001 | link |
| Chlorambucil + obinutuzumab | 105 | — | ||||
| Undetectable MRD in bone marrow at 3 months post-treatment | Ibrutinib + venetoclax | — | 51.9% | — | — | — |
| Chlorambucil + obinutuzumab | — | 17.1% |
Pages like this
not linked directly; found by shared links- TrialCAPTIVATE
Shares BTK inhibitor + venetoclax, fixed duration, Ibrutinib, BTK (Bruton tyrosine kinase), BCL-2.
- TrialAMPLIFY
Shares BTK inhibitor + venetoclax, fixed duration, AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, Obinutuzumab, BTK (Bruton tyrosine kinase).
- TrialCELESTIAL-TNCLL
Shares BTK inhibitor + venetoclax, fixed duration, Obinutuzumab, BTK (Bruton tyrosine kinase), BCL-2.
- TrialCLL13 / GAIA
Shares AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, Obinutuzumab, Ibrutinib, BTK (Bruton tyrosine kinase).
- TrialRESONATE
Shares Ibrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- PairingVenetoclax + obinutuzumab (12 months)
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TrialSEQUOIA
Shares BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), Venetoclax, Chronic lymphocytic leukaemia.
- TrialALPINE
Shares Ibrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.